Role of monocytes and dendritic cells in cardiac reverse remodelling after cardiac resynchronization therapy.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
15 Nov 2023
Historique:
received: 21 07 2023
accepted: 22 10 2023
medline: 27 11 2023
pubmed: 16 11 2023
entrez: 16 11 2023
Statut: epublish

Résumé

Monocytes and dendritic cells (DC) are both key inflammatory cells, with recognized effects on cardiac repair. However, there are distinct subsets of monocytes with potential for beneficial or detrimental effects on heart failure (HF) pathogenesis. The connection between reverse cardiac remodelling, the potential anti-inflammatory effect of cardiac resynchronization therapy (CRT) and monocytes and DC homeostasis in HF is far from being understood. We hypothesized that monocytes and DC play an important role in cardiac reverse remodelling and CRT response. Therefore, we aimed to assess the potential role of baseline peripheral levels of blood monocytes and DC subsets and their phenotypic and functional activity for CRT response, in HF patients. As a secondary objective, we aimed to evaluate the impact of CRT on peripheral blood monocytes and DC subsets, by comparing baseline and post CRT circulating levels and phenotypic and functional activity. Forty-one patients with advanced HF scheduled for CRT were included in this study. The quantification and phenotypic determination of classical (cMo), intermediate (iMo) and non-classical monocytes (ncMo), as well as of myeloid (mDC) and plasmacytoid DC (pDC) were performed by flow cytometry in a FACSCanto™II (BD) flow cytometer. The functional characterization of total monocytes and mDC was performed by flow cytometry in a FACSCalibur flow cytometer, after in vitro stimulation with lipopolysaccharide from Escherichia coli plus interferon (IFN)-γ, in the presence of Brefeldina A. Comparisons between the control and the patient group, and between responders and non-responders to CRT were performed. Compared to the control group, HF population presented a significantly lower frequency of pDC at baseline and a higher proportion of monocytes and mDC producing IL-6 and IL-1β, both before and 6-months after CRT (T6). There was a remarkable decrease of cMo and an increase of iMo after CRT, only in responders. The responder group also presented higher ncMo values at T6 compared to the non-responder group. Both responders and non-responders presented a decrease in the expression of CD86 in all monocyte and DC populations after CRT. Moreover, in non-responders, the increased frequency of IL-6-producing DC persisted after CRT. Our study provides new knowledge about the possible contribution of pDC and monocytes subsets to cardiac reverse remodelling and response to CRT. Additionally, CRT is associated with a reduction on CD86 expression by monocytes and DC subsets and in their potential to produce pro-inflammatory cytokines, contributing, at least in part, for the well described anti-inflammatory effects of CRT in HF patients.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Monocytes and dendritic cells (DC) are both key inflammatory cells, with recognized effects on cardiac repair. However, there are distinct subsets of monocytes with potential for beneficial or detrimental effects on heart failure (HF) pathogenesis. The connection between reverse cardiac remodelling, the potential anti-inflammatory effect of cardiac resynchronization therapy (CRT) and monocytes and DC homeostasis in HF is far from being understood. We hypothesized that monocytes and DC play an important role in cardiac reverse remodelling and CRT response. Therefore, we aimed to assess the potential role of baseline peripheral levels of blood monocytes and DC subsets and their phenotypic and functional activity for CRT response, in HF patients. As a secondary objective, we aimed to evaluate the impact of CRT on peripheral blood monocytes and DC subsets, by comparing baseline and post CRT circulating levels and phenotypic and functional activity.
METHODS METHODS
Forty-one patients with advanced HF scheduled for CRT were included in this study. The quantification and phenotypic determination of classical (cMo), intermediate (iMo) and non-classical monocytes (ncMo), as well as of myeloid (mDC) and plasmacytoid DC (pDC) were performed by flow cytometry in a FACSCanto™II (BD) flow cytometer. The functional characterization of total monocytes and mDC was performed by flow cytometry in a FACSCalibur flow cytometer, after in vitro stimulation with lipopolysaccharide from Escherichia coli plus interferon (IFN)-γ, in the presence of Brefeldina A. Comparisons between the control and the patient group, and between responders and non-responders to CRT were performed.
RESULTS RESULTS
Compared to the control group, HF population presented a significantly lower frequency of pDC at baseline and a higher proportion of monocytes and mDC producing IL-6 and IL-1β, both before and 6-months after CRT (T6). There was a remarkable decrease of cMo and an increase of iMo after CRT, only in responders. The responder group also presented higher ncMo values at T6 compared to the non-responder group. Both responders and non-responders presented a decrease in the expression of CD86 in all monocyte and DC populations after CRT. Moreover, in non-responders, the increased frequency of IL-6-producing DC persisted after CRT.
CONCLUSION CONCLUSIONS
Our study provides new knowledge about the possible contribution of pDC and monocytes subsets to cardiac reverse remodelling and response to CRT. Additionally, CRT is associated with a reduction on CD86 expression by monocytes and DC subsets and in their potential to produce pro-inflammatory cytokines, contributing, at least in part, for the well described anti-inflammatory effects of CRT in HF patients.

Identifiants

pubmed: 37968611
doi: 10.1186/s12872-023-03574-4
pii: 10.1186/s12872-023-03574-4
pmc: PMC10652525
doi:

Substances chimiques

Interleukin-6 0
Anti-Inflammatory Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

558

Informations de copyright

© 2023. The Author(s).

Références

Mayo Clin Proc. 2010 Feb;85(2):180-95
pubmed: 20118395
Cardiology. 2013;124(3):190-8
pubmed: 23486075
PLoS One. 2018 Sep 21;13(9):e0204074
pubmed: 30240448
Brain Commun. 2020 Dec 26;3(1):fcaa215
pubmed: 33501422
Eur J Heart Fail. 2013 Sep;15(9):974-85
pubmed: 23603088
J Am Heart Assoc. 2018 Feb 1;7(3):
pubmed: 29419389
Acta Biomater. 2017 Apr 15;53:13-28
pubmed: 28119112
Eur J Cardiothorac Surg. 2004 Apr;25(4):619-26
pubmed: 15037281
Biomedicine (Taipei). 2020 Jun 05;10(2):36-47
pubmed: 33854919
Circulation. 2009 Oct 6;120(14):1401-14
pubmed: 19770394
Cells. 2021 Dec 09;10(12):
pubmed: 34943990
Cardiovasc Res. 2009 Dec 1;84(3):425-33
pubmed: 19570810
Int J Cardiol. 2009 Jan 9;131(2):246-56
pubmed: 18243370
Eur J Heart Fail. 2011 Nov;13(11):1161-71
pubmed: 21952932
J Educ Eval Health Prof. 2021;18:17
pubmed: 34325496
Circulation. 2012 Mar 13;125(10):1234-45
pubmed: 22308302
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Heart Fail. 2017 Nov;19(11):1379-1389
pubmed: 28891154
Circ Res. 2014 Jun 20;115(1):55-67
pubmed: 24786398
J Neuroimmunol. 2020 Nov 5;350:577433
pubmed: 33176239
Int J Cardiol. 2011 Mar 3;147(2):258-64
pubmed: 19923020
Acta Cardiol. 2016 Apr;71(2):165-72
pubmed: 27090038
Eur J Heart Fail. 2009 Feb;11(2):111-2
pubmed: 19168507
Dis Markers. 2010;28(2):115-24
pubmed: 20364047
Scand J Immunol. 2015 Sep;82(3):163-73
pubmed: 25997925
Med Sci Sports Exerc. 2009 Jan;41(1):3-13
pubmed: 19092709
Cells. 2022 Apr 06;11(7):
pubmed: 35406812
Blood. 2012 Jul 5;120(1):90-9
pubmed: 22611152
Cardiovasc Diabetol. 2018 Oct 22;17(1):137
pubmed: 30348145
Anesth Analg. 2018 Jan;126(1):338-342
pubmed: 29189214
Eur J Heart Fail. 2014 Nov;16(11):1206-13
pubmed: 25302484
Leukemia. 2012 Sep;26(9):1986-2010
pubmed: 22948490
J Interv Card Electrophysiol. 2019 Apr;54(3):257-265
pubmed: 30483979
J Diabetes Res. 2016;2016:7292564
pubmed: 26636106
Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1306-16
pubmed: 25838429
Antioxid Redox Signal. 2009 Aug;11(8):1989-2010
pubmed: 19203220
J Immunol Res. 2016;2016:5946807
pubmed: 27088098
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
Front Physiol. 2014 Jul 25;5:279
pubmed: 25120492
J Cardiovasc Transl Res. 2012 Jun;5(3):309-20
pubmed: 22528677
Pharmacol Res. 2022 Aug;182:106303
pubmed: 35697289
ESC Heart Fail. 2020 Oct;7(5):2305-2317
pubmed: 32619089
Stem Cell Rev Rep. 2018 Oct;14(5):686-693
pubmed: 30022351
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
J Clin Med. 2021 Feb 01;10(3):
pubmed: 33535633
Front Physiol. 2021 Oct 11;12:746494
pubmed: 34707513
Front Pharmacol. 2021 Apr 23;12:565724
pubmed: 33967744
Immunol Res. 2012 Sep;53(1-3):41-57
pubmed: 22430559
Medicine (Baltimore). 2019 Sep;98(38):e17108
pubmed: 31567947
Am J Physiol Cell Physiol. 2021 May 1;320(5):C761-C770
pubmed: 33596150
Stem Cells Int. 2018 Jun 21;2018:1943980
pubmed: 30034479
Adv Med Sci. 2020 Mar;65(1):102-110
pubmed: 31923769
Scand J Immunol. 2008 Feb;67(2):152-9
pubmed: 18201370
Am J Physiol Heart Circ Physiol. 2014 Oct 15;307(8):H1233-42
pubmed: 25128167
BMC Cardiovasc Disord. 2023 Feb 15;23(1):89
pubmed: 36792985
World J Cardiol. 2010 Nov 26;2(11):357-64
pubmed: 21179302
Cardiovasc Diabetol. 2017 Jun 9;16(1):75
pubmed: 28599667
J Mol Cell Cardiol. 2015 Dec;89(Pt B):136-45
pubmed: 26519109
Stem Cell Res Ther. 2020 May 24;11(1):194
pubmed: 32448383
Immunity. 2016 Mar 15;44(3):450-462
pubmed: 26982353
Annu Rev Physiol. 2003;65:81-101
pubmed: 12500970
Immunology. 2013 Sep;140(1):22-30
pubmed: 23621371
Rheumatol Int. 2012 Apr;32(4):863-9
pubmed: 21221593
Clin Rev Allergy Immunol. 2002 Dec;23(3):325-40
pubmed: 12402415
Clin Transl Immunology. 2020 May 26;9(5):e1139
pubmed: 32489664
Europace. 2022 Apr 5;24(4):699
pubmed: 35253863

Auteurs

Sílvia Martins (S)

Health Sciences Research Centre, University of Beira Interior (CICS-UBI), 6200-506, Covilhã, Portugal.
Instituto Politécnico de Castelo Branco, ESALD-Dr. Lopes Dias Health School, Ciências Biomédicas Laboratoriais, Castelo Branco, Portugal.
Department of Clinical Pathology, Centro Hospitalar Universitário Cova da Beira, Quinta Do Alvito, 6200-251, Covilhã, Portugal.
University of Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, Coimbra, Portugal.

Natália António (N)

Cardiology Department, Centro Hospitalar E Universitário de Coimbra, Coimbra, Portugal.
Institute of Pharmacology and Experimental Therapeutics/iCBR, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

Ricardo Rodrigues (R)

Department of Clinical Pathology, Centro Hospitalar Universitário Cova da Beira, Quinta Do Alvito, 6200-251, Covilhã, Portugal.

Tiago Carvalheiro (T)

Centro Do Sangue E da Transplantação de Coimbra, Instituto Português Do Sangue E da Transplantação, Coimbra, Portugal.

Cândida Tomaz (C)

Health Sciences Research Centre, University of Beira Interior (CICS-UBI), 6200-506, Covilhã, Portugal.
Chemistry Department, University of Beira Interior, Covilhã, Portugal.

Lino Gonçalves (L)

Cardiology Department, Centro Hospitalar E Universitário de Coimbra, Coimbra, Portugal.
Institute of Pharmacology and Experimental Therapeutics/iCBR, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

Artur Paiva (A)

University of Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, Coimbra, Portugal. artur.paiva@chuc.min-saude.pt.
Department of Clinical Pathology, Flow Cytometry Unit, Centro Hospitalar E Universitário de Coimbra, Coimbra, Portugal. artur.paiva@chuc.min-saude.pt.
Instituto Politécnico de Coimbra, ESTESC-Coimbra Health School, Ciências Biomédicas Laboratoriais, Coimbra, Portugal. artur.paiva@chuc.min-saude.pt.
Unidade Funcional de Citometria de Fluxo, Centro Hospitalar E Universitário de Coimbra, Praceta Mota Pinto, 3000-075, Coimbra, Portugal. artur.paiva@chuc.min-saude.pt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH